Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that its lead candidate, Telomir-Zn, suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models. The findings, published in the Journal of Oncology Research and Therapy, highlight the compound's ability to selectively modulate intracellular iron and copper, which may offer a new therapeutic approach for aggressive cancers.
The study revealed that Telomir-Zn inhibits histone demethylases by depleting intracellular iron, a mechanism that selectively kills iron-dependent TNBC cells while sparing normal cells at concentrations more than 50-fold higher. In prostate cancer models, the treatment reactivated tumor-suppressor genes, suggesting a potential epigenetic regulatory effect. These results are significant because TNBC is notoriously difficult to treat due to its lack of targeted receptors, and current chemotherapy options often come with severe side effects.
In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. Notably, combining Telomir-Zn with paclitaxel in BT-549 xenografts produced significantly greater tumor reduction than either treatment alone, indicating a potential synergistic effect that could enhance the efficacy of existing chemotherapy. However, MDA-MB-231 xenografts did not respond, underscoring tumor-specific differences in sensitivity that will be important to consider in patient selection for future clinical trials.
“These peer-reviewed findings provide the scientific foundation for advancing Telomir-Zn toward our planned Phase 1/2 clinical trial in TNBC under our active Investigational New Drug application,” said a company spokesperson. The company has already received IND clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer.
The implications of this announcement are considerable for the biotechnology sector. Telomir-Zn's novel mechanism of action—targeting metal homeostasis and epigenetic regulation—represents a departure from traditional cancer therapies. If successful in clinical trials, it could offer a new option for patients with limited alternatives. Moreover, the data suggesting synergy with paclitaxel could lead to combination regimens that improve outcomes and potentially reduce required doses of chemotherapy, thereby diminishing toxicity.
For more information on the full press release, visit https://ibn.fm/mv3hn. The latest news and updates on Telomir Pharmaceuticals are available at https://ibn.fm/TELO.
